Immunostaining and in-situ Hybridization

Immunohistochemistry (IHC), Immunofluorescence (IF) and in-situ Hybridization (ISH):

IHC uses antibodies to detect specific proteins in tissue sections, aiding in disease diagnosis and biomarker research. IF detects specific proteins or cellular structures using fluorophore-conjugated antibodies. ISH is used to detect and localize specific nucleic acid sequences (RNA or DNA) within tissue sections or cells.

TACMASR offers antibody and probe optimization and validation using the automated staining platform Leica Bond RXm. Multiplex staining is also available.

Antibody and IHC consultation services:

Choosing the right antibody is crucial for reliable and reproducible results. Our expert consultation service helps to ensure you select the most suitable primary and secondary antibodies based on your target protein, sample type, and detection method. Request an onsite or remote consultation service here: UACC-TACMASS@uacc.arizona.edu

GeoMx and CosMx Spatial Transcriptomics:

Cutting-edge technology that combines gene expression profiling with tissue morphology, allowing for high-resolution mapping of RNA expression within tissue sections. This provides crucial insights into cellular interactions, tissue architecture, and disease microenvironments.

In collaboration with the Flow Cytometry Immune Monitoring Shared Resource (FCIMSR), TACMASR offers GeoMx and CosMx (NanoString) tissue section preparation and staining of FFPE and frozen tissue samples.

To build a project, get a quote, or order a service within iLab:

Step 1: Select “About Our Core” to learn more about this Shared Resource.
Step 2: Login or sign up for an iLab account at the University of Arizona. For login help, email iLab-support@agilent.com.
Step 3: Once the login step is completed, obtaining prices, services and scheduling is available within the iLab system.

Please remember to acknowledge the Cancer Center Support Grant (P30 CA023074) when publishing manuscripts or abstracts that utilized the services of the University of Arizona Cancer Center’s Shared Resources and/or were derived from CCSG pilot funds. Suggested language: "Research reported in this [publication/press release] was supported by the National Cancer Institute of the National Institutes of Health under award number P30 CA023074.